Pharmanovia Acquires CNS Portfolio From Sanofi
Pharmanovia announced on September 18 the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi. According to data captured in the LevinPro HC database, this transaction is the 75th Pharmaceutical acquisition of 2023. Sanofi is selling a portfolio of CNS brands, including Frisium®, Sentil®, Urbanyl®, Urbanil®, Urbanol®, Urbadan®, Noiafren®, Castilium®, Gardenal®, Tercian® and Stemetil®. The brands span four therapy areas of ongoing unmet need associated with CNS disorders – psycholeptic, anxiolytic, anti-epileptic and anti-psychotic. Pharmanovia (formerly known as Atnahs Pharma UK Limited) is a... Read More »
Sanofi Buys Tidal Therapeutics
The global pharmaceutical company Sanofi (NYSE: SNY) has announced the acquisition of Tidal Therapeutics, a biotechnology firm based in Cambridge, Massachusetts. Sanofi is paying $160 million upfront and up to $310 million upon achievement of certain milestones. Tidal Therapeutics is focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases. The company was seeded by Mission BioCapital, and joined by RA Capital, New Enterprise Associates, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy, MRL Ventures and AbbVie Ventures. The new technology platform will... Read More »
Sanofi Inks New Licensing Deal
Just weeks following its agreement with Translate Bio (NASDAQ: TBIO) for COVID-19 vaccine development, Sanofi (NYSE: SNY) has a new agreement with Kymera Therapeutics Inc. Sanofi and Kymera are signing a multi-program collaboration to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. IRAK4 is believed to play a key role in multiple immune-inflammatory diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales milestones, as well as significant... Read More »